The DCGI-approved anti-coronary capsule "molnupiravir", which is currently on the rise in the country, is set to become available in the Indian market today. The cost of the capsule is Rs 83 per capsule in a medical store, and the pharmaceutical company has made it clear that it cannot be sold without a doctor's prescription. The Expert Committee of the CDCCSCO, a central drug regulatory body, recently recommended the use of Molnupirabi capsules in an emergency.
In view of the urgency and medical need of COVID-19, the committee recommended that the country be allowed to use the drug in case of emergency coronary artery disease. It is recommended that you use this medication for people with chronic and serious illnesses.
There are also clear instructions that children under the age of 18 cannot use it under any circumstances. According to the State Vaccination Nodal Officer, the school will be able to register by showing the school ID card from January 1, while the children will be vaccinated from January 3 to 15-16.